Clene Inc. Advances Neurodegenerative Disease Treatment with FDA-Backed Biomarker Analysis

Clene Inc. (NASDAQ: CLNN) is making strides in the treatment of neurodegenerative diseases with its lead drug candidate, CNM-Au8, following constructive feedback from the FDA. The company plans to start neurofilament biomarker analyses in early Q4 2025, focusing on the neurofilament light chain (NfL) among nearly 200 ALS patients treated under the Expanded Access Program. This initiative underscores the potential of CNM-Au8 to offer new hope to individuals suffering from ALS and other neurodegenerative conditions.

The FDA's collaborative approach has been pivotal in shaping the analysis plan for NfL, a recognized marker for neurodegeneration. Benjamin Greenberg, MD, Head of Medical at Clene, expressed optimism about the progress, highlighting upcoming FDA meetings to discuss long-term ALS survival results and End-of-Phase 2 MS results. These developments are critical for advancing Clene's ALS and MS programs, aiming to deliver groundbreaking therapies to patients in need.

For more details on Clene's innovative approach to treating neurodegenerative diseases, visit https://ibn.fm/t3Lli.